⌕
SI-BONE · SIBN · Nasdaq
Tenet 54 · Mixed
Compare
$23.41−0.13%At closeTenet 54 · Mixed
$23.41−0.03 (−0.13%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

SI-BONE (SIBN) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~22.2%/yr (FY21→FY25), net margin −9.4%. Worth your attention in FY25: Share count (+29.6%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲20.2%
200.9
FY21→FY25CAGR +22.2%/yr
Net income ($M)▲38.8%
−18.9
FY21→FY25CAGR —
Free cash flow ($M)▲60.3%
−9.1
FY21→FY25CAGR —
Diluted EPS▲41.3%
−0.44
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+29.6%

33.1mn → 43.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$8.4M

−19.8% YoY in FY25 · 4.2% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)200.9Revenue−41.0COGS159.9Gross profit−17.4R&D−40.5SG&A−22.3Op income3.4Tax & other−18.9Net income

-9¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
906845230%sector median net margin ~4%FY21FY25

Over this window: gross 88.4% → 79.6%. Net margin -9.4% is below the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
220.7200.9167.2138.9106.490.2▲20.2%+22.2%
Cost of revenue
45.541.035.129.515.710.4▲17.1%+40.9%
Gross profit
175.2159.9132.1109.490.779.7▲21.0%+19.0%
Research & development
18.317.416.615.013.612.4▲5.4%+8.8%
Selling, general & admin
40.140.533.831.129.025.1▲20.1%+12.8%
Total operating expenses
191.9182.2167.4156.4150.3131.4▲8.9%+8.5%
Operating incomefeeds ROC rank
−16.7−22.3−35.2−46.9−59.6−51.7▲36.6%—
Other income, net
3.03.44.33.6−1.5−4.9——
Pretax income
−13.7−18.9−30.9−43.3−61.1−56.6▲38.8%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−13.7−18.9−30.9−43.3−61.3−56.6▲38.8%—
Per share
Diluted EPSbuyback-sensitive
−0.31−0.44−0.75−1.13−1.79−1.71▲41.3%—
Diluted shares (mn)
44.9042.9641.4738.4334.2033.15▲3.6%+6.7%
Margins
Gross margin73rd pct in Healthcare
79.4%79.6%79.0%78.8%85.2%88.4%▲0.5pp−8.9pp
Operating margin
−7.6%−11.1%−21.1%−33.8%−56.0%−57.3%▲10.0pp+46.2pp
Net margin31st pct in Healthcare
−6.2%−9.4%−18.5%−31.2%−57.6%−62.8%▲9.1pp+53.3pp
† TTM = trailing four quarters through 2026-09-30.
FY17 – FY20 · 4 more years
Unlock the full history →
4 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-24 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was SI-BONE's revenue last fiscal year?

SI-BONE reported revenue of $200.9M in fiscal 2025, up 20.2% from fiscal 2024.

What was SI-BONE's net income?

SI-BONE reported net income of −$18.9M in fiscal 2025, a net margin of −9.4%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.